

Gastroenterology

Volume 163 / Number 6 — December 2022

www.gastrojournal.org

Contents

ON THE COVER



More Pieces to the Puzzle: Reducing Death & Transplant in PBC. See article by Murillo Perez and Fisher, et al, page 1630 for additional information.

IN MEMORIAM

1475 In Memoriam—Helen J. Cooke (1943–2021)

H. V. Carey and H. E. Raybould

DIVERSITY, EQUITY, AND INCLUSION IN GI

1477 The AGA Equity Project: Where We Are, and Where We Go From Here

S. M. Quezada, J. M. Carethers, M. Abreu, W. Hendersen, M. B. Omary, and B. Cryer, Equity Project Advisory Board

EDITORIALS

1482 Is Selectivity the JAKpot Winner for Inflammatory Bowel Disease Treatment?

F. D'Amico, L. Peyrin-Biroulet, and S. Danese

See Chen B et al on page 1555.

1485 The Use of Intestinal Ultrasound in Ulcerative Colitis—More Than a Mucosal Disease?

C. Palmela and C. Maaser

See de Voogd F et al on page 1569.

1488 One and Done: Is Measurement of the Rectoanal Pressure Gradient Enough to Diagnose Defecatory Disorders and Guide the Management of Constipation?

H. Heinrich and M. Fox

See Blackett RW et al on page 1582.

1491 The Potential Synergy of Using Interventional and Observational Data to Study Clinically Meaningful, Long-term Outcomes in Rare Liver and Luminal Diseases

T. Bittermann

See Murillo Perez CF et al on page 1630.

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc, 230 Park Avenue, New York, NY 10169-0901, USA. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 1799 Highway 50 East, Linn, MO 65051, USA. 2022 US subscription rates: individual, \$739.00; student and resident, \$282.00. Outside of the U.S. and possessions: individual, \$968.00; student and resident, \$562.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

1492 No Necroptosis in Hepatocytes: The Final Nail in the Coffin?*L. Dara*

See Preston SP et al on page 1643.

1495 A Tale of Two Fibers: A Liver Twist!*A. Zekry and E. M. El-Omar*

See San Yeoh B et al on page 1658.

ELECTRONIC CLINICAL CHALLENGES AND IMAGES IN GIFor a full list, please see the table of contents online at www.gastrojournal.org.**PRACTICAL TEACHING CASES****1498 Evaluation and Treatment of GI Bleeding in a 51-Year-Old Man**

CME

*J. Robbins, I. El Hassan, and C. Siebenburgen***1502 An Unusual Cause of Gastric Variceal Bleeding**

CME

*Y. Zhu, H. Shi, and S. He***MEETING SUMMARY****1505 A Summary of the BRIDGE Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities***N. Krugliak Cleveland, B. Bressler, and C. A. Siegel, on behalf of the BRIDGE UC Progression Summit Collaborators***ORIGINAL RESEARCH****Full Reports****Celiac Disease****1510 Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge**

www

J. A. Murray, J. A. Syage, T.-T. Wu, M. A. Dickason, A. G. Ramos, C. Van Dyke, I. Horwath, P. T. Lavin, M. Mäki, I. Hujoel, K. A. Papadakis, A. C. Bledsoe, C. Khosla, and J. A. Sealey-Voyksner, on behalf of the CeliacShield Study Group

Latiglutenase is given orally, protects the small intestine, and reduces symptoms induced by gluten challenge without significant side effects in patients with celiac disease.

GI Cancer**1522 Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts**

www

K. Yang, Y. Cao, C. Gurjao, Y. Liu, C.-G. Guo, C.-H. Lo, X. Zong, D. Drew, C. Geraghty, E. Prezioso, M. Moore, C. Williams, T. Riley, M. Saul, S. Ogino, M. Giannakis, A. Bass, R. E. Schoen, and A. T. Chan

Colorectal cancers diagnosed between screening examinations (interval cancers) had significantly increased risk of death than screen detected cancers, although no significant molecular differences were observed between them at a whole exome sequencing level.

1531 Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival

www

R. K. Pai, I. Banerjee, S. Shivji, S. Jain, D. Hartman, D. D. Buchanan, M. A. Jenkins, D. F. Schaeffer, C. Rosty, J. Como, A. I. Phipps, P. A. Newcomb, A. N. Burnett-Hartman, L. Le Marchand, N. J. Samadder, B. Patel, C. Swallow, N. M. Lindor, S. J. Gallinger, R. C. Grant, T. Westerling-Bui, J. Conner, D. P. Cyr, R. Kirsch, and R. K. Pai

We demonstrate that quantitative analysis of digitized images of colorectal carcinoma can improve prediction of tumor recurrence and place tumors into clinically relevant prognostic risk groups.

Inflammatory Bowel Disease

1547 The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study

CME WWW

M. Agrawal, H. S. Christensen, M. Bøgsted, J.-F. Colombel, T. Jess, and K. H. Allin

Analysis of Danish nationwide data with follow-up over 2 decades show that inflammatory bowel disease incidence and prevalence are increasing and that the inflammatory bowel disease population is shifting toward an older age.

1555 Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study

WWW E

B. Chen, J. Zhong, X. Li, F. Pan, Y. Ding, Y. Zhang, H. Chen, F. Liu, Z. Zhang, L. Zhang, R. Drozda, O. Oliynyk, A. H. Goh, X. Chen, X. Sun, D. T. Rubin, W. J. Sandborn, and M. Chen

See editorial on page 1482.

Oral ivarmacitinib was found to be a safe and effective therapy for adult patients with moderate-to-severe, active ulcerative colitis, and holds promise as a new treatment option for this condition.

1569 Intestinal Ultrasound Is Accurate to Determine Endoscopic Response and Remission in Patients With Moderate to Severe Ulcerative Colitis: A Longitudinal Prospective Cohort Study

WWW E

F. de Voogd, E. A. van Wassenae, A. Mookhoek, S. Bots, S. van Gennep, M. Löwenberg, G. R. D'Haens, and K. B. Gecse

See editorial on page 1485.

Bowel ultrasound detects response to treatment in patients with ulcerative colitis and corresponds well with endoscopy. It could be used as a noninvasive alternative to endoscopy in treatment response evaluation.

Functional GI Disease

1582 Comparison of Anorectal Manometry, Rectal Balloon Expulsion Test, and Defecography for Diagnosing Defecatory Disorders

CME WWW

E

J. W. Blackett, M. Gautam, R. Mishra, N. R. Oblizajek, S. Kathavarayan Ramu, K. R. Bailey, and A. E. Bharucha

See editorial on page 1488.

A reduced rectoanal gradient, compared with age- and sex-matched asymptomatic individuals, was the most important parameter on anorectal manometry to predict impaired evacuation by balloon expulsion test or defecography and should be considered probable evidence of a defecatory disorder.

Pancreas

1593 Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer

WWW

J. Datta, X. Dai, A. Bianchi, I. De Castro Silva, S. Mehra, V. T. Garrido, P. Lamichhane, S. P. Singh, Z. Zhou, A. R. Dosch, F. Messaggio, Y. Ban, O. Umland, P. J. Hosein, N. S. Nagathihalli, and N. B. Merchant

This study highlights the novel role of combination targeted therapies that reprogram tumor-permissive cancer-associated fibroblasts and suppressive immune microenvironments to invigorate antitumor immune responses, thereby sensitizing pancreatic cancers to immunotherapy.

1613 Context-Dependent Roles of *Hes1* in the Adult Pancreas and Pancreatic Tumor Formation

WWW

S. Marui, Y. Nishikawa, M. Shiokawa, M. Yokode, S. Matsumoto, Y. Muramoto, S. Ota, T. Nakamura, H. Yoshida, H. Okada, T. Kuwada, T. Matsumori, K. Kuriyama, A. Fukuda, D. Saur, T. Aoi, N. Uza, Y. Kodama, T. Chiba, and H. Seno

An analysis of the roles of *Hes1* in adult pancreas and pancreatic ductal carcinoma showed that the roles of *Hes1* in pancreas depend on the cellular context and tumor phase.

1630 Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

C. F. Murillo Perez, H. Fisher, S. Hiu, D. Kareithi, F. Adekunle, T. Mayne, E. Malecha, E. Ness, A. J. van der Meer, W. J. Lammers, P. J. Trivedi, P. M. Battezzati, F. Nevens, K. V. Kowdley, T. Bruns, N. Cazzagon, A. Floreani, A. L. Mason, A. Parés, M.-C. Londoño, P. Invernizzi, M. Carbone, A. Lleo, M. J. Mayo, G. N. Dalekos, N. K. Gatselis, D. Thorburn, X. Verhelst, A. Gulamhusein, H. L. A. Janssen, R. Smith, S. Flack, V. Mulcahy, M. Trauner, C. L. Bowlus, K. D. Lindor, C. Corpechot, D. Jones, G. Mells, G. M. Hirschfield, J. Wason, and B. E. Hansen, on behalf of GLOBAL PBC Study Group and the members of the UK-PBC Consortium

See editorial on page 1491.

Patients with primary biliary cholangitis treated with obeticholic acid in the POISE study had fewer deaths and liver transplants vs comparable patients in the Global PBC and UK-PBC disease registries.

1643 Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver Pathologies

S. P. Preston, M. D. Stutz, C. C. Allison, U. Nachbur, Q. Gouil, B. M. Tran, V. Duvivier, P. Arandjelovic, J. P. Cooney, L. Mackiewicz, Y. Meng, J. Schaefer, S. M. Bader, H. Peng, Z. Valaydon, P. Rajasekaran, C. Jenkinson, S. Lopatnicki, A. Farrell, M. Ryan, J. Howell, C. Croagh, D. Karunakaran, C. Schuster-Klein, J. M. Murphy, T. Fifis, C. Christophi, E. Vincan, M. E. Blewitt, A. Thompson, J. A. Boddey, M. Doerflinger, and M. Pellegrini

See editorial on page 1492.

Necroptosis, a form of inflammatory cell death, has no role in causing liver pathology during infection and steatohepatitis.

1658 Enterohepatic Shunt-Driven Cholemia Predisposes to Liver Cancer

B. S. Yeoh, P. Saha, R. M. Golonka, J. Zou, J. L. Petrick, A. A. Abokor, X. Xiao, V. R. Bovilla, A. C. A. Bretin, J. Rivera-Esteban, D. Parisi, A. A. Florio, S. J. Weinstein, D. Albanes, G. J. Freeman, A. F. Gohara, A. Ciudin, J. M. Pericàs, B. Joe, R. F. Schwabe, K. A. McGlynn, A. T. Gewirtz, and M. Vijay-Kumar

See editorial on page 1495.

A specific defect in the enterohepatic circulation of bile acids is a cause for liver cancer, which is mediated through induction of liver injury and compensatory immunosuppression.

RESEARCH LETTERS**1672 Durability of Immunity Is Low Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1, BA.2, and BA.3 Variants After Second and Third Vaccinations in Children and Young Adults With Inflammatory Bowel Disease Receiving Biologics**

L. Bellusci, F. T. Zahra, D. E. Hopkins, J. C. Salazar, J. S. Hyams, and S. Khurana

1676 Rural-Urban Disparities in Mortality and Place of Death for Gastrointestinal Cancer in the United States From 2003 to 2019

S. M. Q. Hussaini, A. L. Blackford, N. Arora, R. Sedhom, M. S. Beg, and A. Gupta

1679 ALDH1A1 Expression Is Enriched in Early-Onset Colorectal Cancers

A. Venugopal, M. Koi, C. Choi, H.-R. Kim, E. K. Speliotes, and J. M. Carethers

1682 Clinically Significant Metachronous Colorectal Pathology Detected Among Young-Onset Colorectal Cancer Survivors: Implications for Post-Resection Surveillance Guidelines

O. Peacock, E. Vilar, M. Guraieb-Trueba, S. Thirumurthi, G. J. Chang, and Y. N. You

1685 Coronavirus Disease 2019 Pandemic-related Colorectal Cancer Screening Delays Impact Unscreened Older Adults the Most, But Mitigation Strategies Exist

R. N. Sharaf, S. Sinha, Z. Li, A. Bar-Mashiah, and U. Ladabaum

1688 Extracellular Matrix Interactions Provide Tumor Cells With an Escape Mechanism for Commitment to Differentiation

www

P. J. Schweiger, M. Le Bouteiller, S. Yui, M. Thodberg, D. Clement, and K. B. Jensen

1691 Noncoding Aberrations in Mismatch Repair Genes Underlie a Substantial Part of the Missing Heritability in Lynch Syndrome

www

I. B. A. W. Te Paske, A. R. Mensenkamp, K. Neveling, ERN-GENTURIS Lynch-Like Working Group, N. Hoogerbrugge, M. J. L. Ligtenberg, and R. M. De Voer

AGA SECTION

1695 GI Multisociety Strategic Plan on Environmental Sustainability

www

H. Pohl, R. de Latour, A. Reuben, N. K. Ahuja, S. Gayam, R. Kohli, D. Agrawal, and M. B. Omary

1702 Diversity, Equity, and Inclusion in Gastroenterology and Hepatology: A Survey of Where We Stand

www

H. K. Rahal, J. H. Tabibian, R. B. Issaka, S. Quezada, D. M. Gray II, S. Balzora, L. Yang, J. Badiee, and F. P. May

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e38 CME Exam 1: Evaluation and Treatment of GI Bleeding in a 51-Year-Old Man

e40 CME Exam 2: An Unusual Cause of Gastric Variceal Bleeding

e41 CME Exam 3: The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study

e42 CME Exam 4: Comparison of Anorectal Manometry, Rectal Balloon Expulsion Test, and Defecography for Diagnosing Defecatory Disorders

GASTRO DIGEST

1712 Engineering Microbes to Combat Antibiotic-induced Dysbiosis: Implications for Gastroenterology

E. Wine

1712 Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer

A. D'Alessio and D. J. Pinato

1713 Cancer Risk Following Bariatric Surgery

M. Arvanitakis

1714 Endoscopist Adenoma Detection Rates and Their Correlation With Postcolonoscopy Colorectal Cancer

N. Forbes

CORRESPONDENCE

1716 Proton Pump Inhibitors Increasing the Risk of Infection and Mortality in Cirrhosis—We Need a Closer Look!

S. P. Singh

1716 Proton Pump Inhibitors for Patients With Cirrhosis: Good Medicine or Poison?

J. Wang, D. Liu, and S. Chen

1717 The Beauty and Sorrow of Using Proton Pump Inhibitors in Patients With Cirrhosis

G.-H. Lo

- 1718 Reply**
N. Mahmud, M. Serper, and D. E. Kaplan
- 1719 Histologic Evaluation of Eosinophilic Esophagitis as Part of the Recently Proposed Clinical Severity Index**
M. Younes, S. A. Schueler, and M. L. Borum
- 1720 Reply**
E. S. Dellon, M. H. Collins, G. T. Furuta, and S. S. Aceves

Access to the full content of Gastroenterology Online is available to all subscribers!

AGA members have seamless access to full *Gastroenterology* content from the AGA Web site. Simply sign in to <http://www.gastro.org>, visit the Publications section of the Web site, and click on *Gastroenterology*. You will be directed to the Journal Web site and will have full access to all content without having to supply a different username and password. Members can also visit <http://www.gastrojournal.org> directly and click on "Activate Online Access." Nonmember subscribers must create an online user account and activate their subscription to access the full text of articles on *Gastroenterology* Online. To activate your individual online subscription, please visit <http://www.gastrojournal.org> and click on "Activate Online Access." To activate your account, you

will need your subscriber account or member number, which you can find on your mailing label, (AGA members must use their 10-digit member number, including leading zeros). If you have any questions regarding your online subscription please call Elsevier Customer Service at (800) 654-2452.

Institutional access to *Gastroenterology* Online will be allowed only by limited site licensing. Further instructions will be available online. Personal subscriptions to *Gastroenterology* Online are for individual use only and may not be transferred. Use of *Gastroenterology* Online is subject to agreement to the terms and conditions of use as indicated online.

AGA Member Number

Your Account Number

Sample
mailing
label

GAST0000101864
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001

1GAST V91-4 1234567-8
JANE DOE
531 MAIN ST
CENTER CITY, NY 10001-001